This inventor holds 1 USPTO granted patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Hyung Gee Kim: Innovator in Cancer Research
Introduction
Hyung Gee Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research through his innovative work on Bcl2L12 polypeptides. His research focuses on the biological activities of these polypeptides and their potential applications in cancer treatment.
Latest Patents
Hyung Gee Kim holds 1 patent related to his invention of Bcl2L12 polypeptide activators and inhibitors. This invention provides methods and materials for identifying activators and inhibitors of Bcl2L12 polypeptide activities, which include the ability to block apoptosis and promote cell growth and transformation. Furthermore, the invention outlines methods for treating mammals with cancer, showcasing its potential impact on therapeutic strategies.
Career Highlights
Hyung Gee Kim is affiliated with the Dana-Farber Cancer Institute, where he continues to advance his research in cancer biology. His work has garnered attention for its innovative approach to understanding and manipulating cellular processes related to cancer.
Collaborations
He collaborates with notable colleagues, including Alex Stegh and Lynda Chin, who contribute to the research environment at the Dana-Farber Cancer Institute. Their combined expertise enhances the potential for groundbreaking discoveries in cancer treatment.
Conclusion
Hyung Gee Kim's contributions to cancer research through his innovative patents and collaborations highlight the importance of scientific advancements in the fight against cancer. His work exemplifies the potential of targeted therapies in improving patient outcomes.